Market Size of Human Respiratory Syncytial Virus Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 10.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Human Respiratory Syncytial Virus Treatment Market Analysis
The human respiratory syncytial virus (RSV) treatment market is expected to register a CAGR of 10% during the forecast period.
COVID-19 had a notable impact on the human respiratory syncytial virus treatment market. The viral interference can alter the pattern and dynamics of syncytial virus infection. For instance, as per the article published in December 2021 in PubMed, the COVID-19 pandemic drastically changed the epidemiology of other viral respiratory infections including RSV in both children and adults. As per the same source, the rhinovirus could compete with other respiratory viruses and change the epidemic dynamics. Thus, during the pandemic, the delayed onset of the infection, as well as the limited number of cases reported, could be attributed to viral interference. However, as the restrictions are eased, the human respiratory syncytial virus treatment market is expected to witness growth in the coming years due to the rise in the prevalence of respiratory syncytial virus and the increase in technological advances in treatment.
Factors such as the rise in the prevalence of RSV and the increase in government support and funding for the development of RSV treatment are expected to drive market growth. For instance, as per the article published in November 2022 in MedRxiv, there were significant racial and ethnic disparities in the peak RSV infection rate during 2010-2021 and the disparities were further exacerbated in 2022 with a peak incidence rate in black and Hispanic children 2-3 times that in white children. Among RSV-infected children in 2022, 19.2% had prior documented COVID-19 infection, significantly higher than the 9.7% among uninfected children, suggesting that prior COVID-19 could be a risk factor for RSV infection or that there are common risk factors for both viral infections. Furthermore, as per the CDC's October 2022 update, in the 2022-2023 season, the overall rate of RSV-associated hospitalization was 43.4 per 100,000 people. Thus, such a rise in RSV infections is likely to increase the demand for proper treatment and thereby drive market growth.
Moreover, the increase in research and development and pipeline assets for RSV treatment by the key players are expected to promote market growth over the forecast period. For instance, in October 2022, GSK's older adult respiratory syncytial virus (RSV) vaccine candidate showed a 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in the pivotal trial. The data presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favorable safety profile.
Hence, a rise in RSV infection and an increase in pipeline assets by the key players are expected to increase the growth of the studied market over the forecast period. However, less availability of safe and effective antiviral drugs can hinder the market growth over the study period.
Human Respiratory Syncytial Virus Treatment Industry Segmentation
As per the scope of the report, respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. The Human Respiratory Syncytial Virus Treatment Market is Segmented by Route of Administration (Oral, Parenteral), Treatment Type (Supportive Care, Hospital Care), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the value (in USD million) for all the above segments.
| By Route of Administration | |
| Oral | |
| Parenteral |
| By Treatment Type | |
| Supportive Care | |
| Hospital Care |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Human Respiratory Syncytial Virus Treatment Market Size Summary
The human respiratory syncytial virus (RSV) treatment market is poised for significant growth, driven by an increase in RSV prevalence and advancements in treatment technologies. The market is experiencing a resurgence as COVID-19 restrictions ease, leading to a rise in RSV infections. This has been further exacerbated by disparities in infection rates among different racial and ethnic groups, highlighting the need for effective treatments. The market is also benefiting from increased government support and funding for RSV treatment development. Key players in the industry are actively engaged in research and development, with promising pipeline assets such as vaccines and antiviral drugs, which are expected to bolster market expansion over the forecast period.
North America is anticipated to maintain a substantial share of the RSV treatment market, supported by a rise in infections, robust research and development activities, and the presence of major industry players. The region's healthcare expenditure and ongoing clinical studies, such as those by GSK and Pfizer, are expected to drive market growth. The fragmented nature of the market sees major companies like AstraZeneca, AbbVie Inc, Merck & Co, GSK plc, and Bausch Health Companies Inc. leading the charge with innovative treatments and regulatory approvals. The parenteral segment, in particular, is expected to grow due to the development of vaccines and the increasing demand for effective RSV treatments globally.
Human Respiratory Syncytial Virus Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increased Prevalence of Respiratory Syncytial Virus
-
1.2.2 Government Funding and Initiaves for for RSV treatment
-
-
1.3 Market Restraints
-
1.3.1 Less Availability of Safe and Effective Antiviral Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Route of Administration
-
2.1.1 Oral
-
2.1.2 Parenteral
-
-
2.2 By Treatment Type
-
2.2.1 Supportive Care
-
2.2.2 Hospital Care
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Human Respiratory Syncytial Virus Treatment Market Size FAQs
What is the current Human Respiratory Syncytial Virus Treatment Market size?
The Human Respiratory Syncytial Virus Treatment Market is projected to register a CAGR of 10% during the forecast period (2024-2029)
Who are the key players in Human Respiratory Syncytial Virus Treatment Market?
AbbVie Inc, Merck & Co, AstraZeneca, GSK plc and Bausch Health Companies Inc. are the major companies operating in the Human Respiratory Syncytial Virus Treatment Market.
